Cross-Sector entity
Of the tracked stories, 2 of 2 also mention 2024-2025 COVID-19 Vaccine, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. Influenza Vaccine appears in 2 tracked Cross-Sector stories from June 28, 2026.
2 verified stories tracked
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention 2024-2025 COVID-19 Vaccine, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. Influenza Vaccine appears in 2 tracked Cross-Sector stories from June 28, 2026. The tracked stories average 4 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Influenza Vaccine. Shared-story counts are live from our verified record — not editorial picks.
A massive Veterans Affairs study of over one million veterans reveals the 2024-2025 COVID vaccine significantly reduces cardiovascular events, especially in older adults, offering healthcare systems a new preventive tool.
The 2024-2025 COVID vaccine reduced MACE by 37.7% in a large VA trial, with even greater benefits in high-risk subgroups, sparking biopharma interest in a cardiovascular indication for mRNA vaccines.
Source: wtag.iheart.com · wrno.iheart.com
